Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) shares gapped up before the market opened on Thursday . The stock had previously closed at $9.12, but opened at $9.48. Bavarian Nordic shares last traded at $9.47, with a volume of 963 shares trading hands.
Bavarian Nordic Trading Down 0.7%
The business's 50 day moving average is $8.75 and its two-hundred day moving average is $8.33. The company has a market cap of $2.24 billion, a PE ratio of 11.81 and a beta of 1.36.
Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The company reported $0.13 EPS for the quarter. The business had revenue of $189.89 million for the quarter. Bavarian Nordic had a net margin of 21.11% and a return on equity of 11.89%. As a group, equities research analysts predict that Bavarian Nordic will post 0.67 EPS for the current fiscal year.
About Bavarian Nordic
(
Get Free Report)
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.
See Also
Before you consider Bavarian Nordic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bavarian Nordic wasn't on the list.
While Bavarian Nordic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
